Comparing Treatments for Stage 4 Neuroblastoma in Children
Author Information
Author(s): Luksch R, Podda M, Gandola L, Polastri D, Piva L, Castellani R, Collini P, Massimino M, Cefalo G, Terenziani M, Ferrari A, Casanova M, Spreafico F, Meazza C, Bozzi F, Marchianò A, Ravagnani F, Fossati-Bellani F
Primary Institution: Istituto Nazionale Tumori di Milano
Hypothesis
Does high-dose chemotherapy plus autologous stem cell transplantation improve outcomes compared to sequential hemi-body irradiation in children with stage 4 neuroblastoma?
Conclusion
High-dose chemotherapy with autologous stem cell transplantation significantly improves survival outcomes compared to sequential hemi-body irradiation in children with stage 4 neuroblastoma.
Supporting Evidence
- The 5-year event-free survival probability was 0.12 for the first treatment program and 0.31 for the second.
- Patients treated with high-dose chemotherapy had a significantly better survival rate compared to those treated with hemi-body irradiation.
- All patients received at least two cycles of induction therapy and were evaluable for response.
Takeaway
This study looked at two different treatments for kids with a serious cancer called neuroblastoma. One treatment worked better than the other, helping more kids live longer.
Methodology
The study involved two nonrandomised treatment programs for children with stage 4 neuroblastoma, comparing outcomes of sequential hemi-body irradiation and high-dose chemotherapy with stem cell transplantation.
Potential Biases
Potential bias due to the nonrandomised nature of the treatment programs and the limited number of patients.
Limitations
The study's nonrandomised design and mono-institutional setting may introduce bias.
Participant Demographics
The median age of participants was 3 years, with a male-to-female ratio of 1.3.
Statistical Information
P-Value
0.03
Statistical Significance
p=0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website